Ellicott City, MD – The Society for Clinical Research Sites (SCRS), the global trade organization fully dedicated to representing the interests of clinical research sites, today announced that US Oncology Research joined the more than 2,800 research sites across 42 countries as an SCRS member. US Oncology Research integrates community-based oncology practices into a physician-led network of over 900 experienced investigators. Physicians affiliated with US Oncology Research have enrolled approximately 63,000 patients in nearly 1,500 trials. These physicians share best practices and make clinical research available to communities beyond major research centers. “We are eager to collaborate with SCRS in order to help the industry make improvements in oncology clinical trial execution, in order to help the sites spend more time with patients, and to reduce costs associated with conducting clinical trials,” said Lisa Holland, VP, US Oncology Research. “It is the mission of SCRS to ensure site sustainability,” commented Christine Pierre, SCRS President. “We are excited to welcome US Oncology Research as members. With their collaboration, we are addressing the management needs of community-based research sites and provide solutions to meet the growing demands of oncology research.” About SCRS SCRS is a global trade organization founded in 2012 which represents over 2,800 research sites in 42 countries. SCRS’ mission is to unify the voice of the global clinical research site community for greater site sustainability. SCRS has become an active partner in industry-wide initiatives and dialogues focused on improving the clinical research enterprise. Sites and the companies that sponsor or support the work conducted at clinical research sites will benefit from membership and partnership. Visit MySCRS.org. About US Oncology Research Supported by McKesson Specialty Health and The US Oncology Network, US Oncology Research draws from a network of experienced investigators and dedicated clinical staff who specialize in oncology clinical trials. US Oncology Research serves approximately 60 research sites and nearly 165 locations managing about 300 active trials at any given time. Physicians in the research network have enrolled approximately 63,000 patients in nearly 1,500 trials since its inception in 1992 and have played a role in approximately 60 FDA-approved cancer therapies, nearly one-third of all cancer therapies approved by the FDA to date. For more information visit www.usoncology.com/oncologists.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.